{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:vadastuximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02202759: Phase 2 Interventional Terminated Adenocarcinoma of the Stomach
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01933763: Phase 1 Interventional Completed Healthy Volunteers
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02225366: Phase 1/Phase 2 Interventional Completed Melanoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exbivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00853723: Phase 2 Interventional Completed Osteoporosis
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00568594: Phase 1/Phase 2 Interventional Completed Coronary Heart Disease
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tamtuvetmab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188328: Phase 1 Interventional Terminated Inoperable Solid Tumors or Lymphomas
(2017)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
